API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2021/06/28/2253829/0/en/Denali-Therapeutics-Announces-Initiation-of-Phase-2-Study-by-Partner-Sanofi-of-RIPK1-Inhibitor-DNL758-SAR443122-in-Cutaneous-Lupus-Erythematosus-CLE-Patients.html